/LDXHF
LDXHF Stock - Lumos Diagnostics Holdings Limited
Healthcare|Medical - Diagnostics & ResearchOTC
$0.17-8.11%
$0.01 (-8.11%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.95
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.94
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.19
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LDXHF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.17 – $0.17
TARGET (TP)$0.20
STOP LOSS$0.16
RISK/REWARD1:3.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.64
52W High$0.21
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $12.50M | $11.13M | $10.54M | $11.63M | $18.98M |
| Gross Profit | $7.91M | $7.10M | $-4,282,255 | $4.46M | $638,084 |
| Gross Margin | 63.2% | 63.8% | -40.6% | 38.3% | 3.4% |
| Operating Income | $-7,842,000 | $-7,122,000 | $-6,561,000 | $-23,886,000 | $-11,072,882 |
| Net Income | $-7,183,000 | $-8,592,000 | $-8,882,338 | $-45,724,000 | $-15,126,838 |
| Net Margin | -57.5% | -77.2% | -84.3% | -393.2% | -79.7% |
| EPS | $-0.01 | $-0.02 | $-0.04 | $-0.30 | $-0.09 |
Company Overview
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LDXHFBeat Rate
40%
Last 5 quarters
Avg Surprise
-90.3%
EPS vs Estimate
Beats / Misses
2/3
Last 12 quarters
Latest EPS
$-0.00
Q2 2025
EPS Surprise History
Q4 21
-95.5%
$-0.07vs$-0.03
Q2 22
-431.5%
$-0.22vs$-0.04
Q4 22
+34.7%
$-0.03vs$-0.05
Q2 23
+85.2%
$-0.01vs$-0.05
Q4 23
No data
Q2 24
No data
Q4 24
No data
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Jun 30, 2025 | — | $-0.00 | — | — |
Q4 2024 | Dec 30, 2024 | — | $-0.01 | — | — |
Q4 2024 | Oct 31, 2024 | — | — | — | — |
Q2 2024 | Jun 30, 2024 | — | $-0.00 | — | — |
Q4 2023 | Dec 30, 2023 | — | $-0.01 | — | — |
Q3 2023 | Aug 30, 2023 | $-0.05 | — | — | — |
Q2 2023 | Jun 30, 2023 | $-0.05 | $-0.01 | +85.2% | ✓ BEAT |
Q4 2022 | Dec 30, 2022 | $-0.05 | $-0.03 | +34.7% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-0.04 | $-0.22 | -431.5% | ✗ MISS |
Q4 2021 | Dec 30, 2021 | $-0.03 | $-0.07 | -95.5% | ✗ MISS |
Q2 2021 | Jun 30, 2021 | $-0.05 | $-0.07 | -44.7% | ✗ MISS |
Q4 2020 | Dec 30, 2020 | — | $-0.02 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.03 | — | — |
Q4 2019 | Dec 30, 2019 | — | $-0.03 | — | — |
Latest News
Loading news...
Frequently Asked Questions about LDXHF
What is LDXHF's current stock price?
Lumos Diagnostics Holdings Limited (LDXHF) is currently trading at $0.17 per share. The stock has moved -8.11% today.
What is the analyst price target for LDXHF?
No analyst price targets are currently available for this stock.
What sector is Lumos Diagnostics Holdings Limited in?
Lumos Diagnostics Holdings Limited operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the OTC exchange.
What is LDXHF's market cap?
Lumos Diagnostics Holdings Limited has a market capitalization of $0.13 billion, making it a small-cap company.
Does LDXHF pay dividends?
No, Lumos Diagnostics Holdings Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCORBF
Global Cord Blood Corporation
$0.75
Mkt Cap: $0.1B
ORXOF
Orexo AB (publ)
$3.05
Mkt Cap: $0.1B
PBIGF
Paradigm Biopharmaceuticals Limited
$0.23
Mkt Cap: $0.1B
PFGTF
Pacific Edge Limited
$0.10
Mkt Cap: $0.1B
SHIEF
Shield Therapeutics plc
$0.09
Mkt Cap: $0.1B
SNZZF
Senzime AB (publ)
$0.45
Mkt Cap: $0.1B
SPHRF
Starpharma Holdings Limited
$0.25
Mkt Cap: $0.1B
THOXF
BioPorto A/S
$0.29
Mkt Cap: $0.1B
TOKIF
Optima Medical Innovations Corp.
$0.01
Mkt Cap: $0.1B
VTIAF
FamiCord AG
$6.38
Mkt Cap: $0.1B
Explore stocks similar to LDXHF for comparison